Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Mont–Saint–Guibert, Belgium "" February 4, 2022, 10:30pm CET / 4:30pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually from February 15–17, 2022.

Olivier Taelman, Nyxoah's Chief Executive Officer, is scheduled to present a corporate update on Thursday, February 17, 2022, at 8:00am EST. This presentation will not be webcast due to the format of the conference. The Company will also be available for virtual 1×1 meetings with institutional investors registered for the event.

Nyxoah's updated Investor Presentation can be accessed on the Shareholder Information section of the Company's Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Loic Moreau, Chief Financial Officer
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
+1 917 749 1494

Gilmartin Group
Vivian Cervantes


Increased Investment Critical to End Female Genital Mutilation as COVID-19 Rages On

In 2012, the United Nations General Assembly designated 6 February as the International Day of Zero Tolerance for Female Genital Mutilation, with the aim of amplifying and directing the efforts on the elimination of this practice. Credit: UNFPA

By Natalia Kanem and Catherine Russell
NEW YORK, Feb 4 2022 – “Multiple overlapping crises are putting millions of girls at increased risk of female genital mutilation. “Countries already grappling with rising poverty, inequality and conflict are seeing the COVID-19 pandemic further threaten years of progress to end the practice, creating a crisis within a crisis for the world’s most vulnerable and marginalized girls.

“Even before COVID-19, 68 million girls were estimated to be at risk of female genital mutilation between 2015 and 2030. As the pandemic continues to shutter schools and disrupt programmes that help protect girls from this harmful practice, an additional 2 million additional cases of female genital mutilation may occur over the next decade.

“Rapid population growth in some countries is expected to further increase the number of girls at risk, adding urgency to the global effort to eliminate the practice by 2030 as set out in the Sustainable Development Goals.

“Female genital mutilation harms girls’ bodies, lives and futures. It is also a violation of their human rights. Only united, concerted and well-funded action can end the practice everywhere.

“As the global community adopts programmes to reach girls and women impacted by the pandemic, there is an urgent need to accelerate investment to end female genital mutilation. Some $2.4 billion are needed to eliminate this practice in 31 high-priority countries. Specifically:

    • Investment in the empowerment of girls and women, and in adequate services and response for those affected and at risk of female genital mutilation
    • Investment in building partnerships and mobilizing allies – including men and boys, women’s groups, community leaders and even former practitioners of female genital mutilation – to help eliminate the practice.
    • Investment in developing and enforcing national-level laws and strengthening institutions.

“So far, progress has been clear and measurable. Today, girls are one third less likely to be subjected to female genital mutilation than 30 years ago, and in the last two decades, the proportion of girls and women in high-prevalence countries who oppose the practice has doubled.

“Those gains now face an unprecedented challenge. Global efforts must keep the momentum moving forward and build on years of progress to end this harmful practice completely.”

Dr. Natalia Kanem is UNFPA Executive Director and Catherine Russell is UNICEF Executive Director.


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);